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M A J O R A R T I C L E
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We investigated the role of interferon (IFN)–g, interleukin (IL)–1b, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, tumor
necrosis factor (TNF)-a, and transforming growth factor (TGF)–b in clinically well-defined groups of Plas-
modium falciparum–infected patients manifesting mild malaria (MM), severe noncerebral malaria (SM), or
cerebral malaria (CM) and in control subjects from Gondia, a malaria-endemic site in India, as well as in
healthy subjects from non–malaria-endemic areas. Two-way coupled cluster analysis revealed 2 clusters of
cytokines relevant to clinical subgroups of disease. The first cluster was composed of IFN-g, IL-2, IL-5, IL-6,
and IL-12, the levels of which were significantly increased during infection but were predominant in patients
with MM and allowed us to distinguish them from patients with SM or CM. The second cluster was composed
of TGF-b, TNF-a, IL-10, and IL-1b, the levels of which were highly correlated with each other in the different
clinical groups of patients and significantly increased with disease severity, particularly in CM. Discriminant
analyses allowed us to propose a minimal model. Levels of cytokines such as IL-5, IL-1b, IL-10, and IL-2
increase with infection. Levels of IL-12, IL-5, and IL-6 discriminate severe forms of malaria from MM. Finally,
levels of IL-1b, IL-12, and IFN-g are relevant for the discrimination of CM from SM: high IL-1b levels are
associated with CM, and high IL-12 and IFN-g levels are associated with SM.
Plasmodium falciparum malaria is a major public-health
problem in sub-Saharan Africa and southern Asia, with
∼1.7 million of the 2 billion people living in these en-
demic areas dying every year as a result of complications
from the disease [1–3]. Although the epidemiological
status of malaria in India is not precisely documented,
the disease is known to be endemic and widespread in
many rural areas of the country as well as in central
India, where the present study was undertaken.
Disease manifestation generally differs from person
to person, ranging from uncomplicated, mild malaria
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(MM) to severe noncerebral malaria (SM) to cerebral
malaria (CM), characterized by neurological signs, re-
peated convulsions, and coma stage II, which can lead
to death. The cause of such differential responses in the
degree of severity, as well as the underlying physio-
pathologic process by which severe P. falciparum ma-
laria progresses to cerebral complications, are not well
understood. There is some evidence suggesting that the
mechanical obstruction of brain microvessels by blood-
stage parasites adhering to the vascular endothelium,
immune responses, and genetic factors in both the
mammalian host and the parasite play specific roles in
disease progression [4, 5]. However, the role of parasite
sequestration in the pathogenesis of CM remains con-
troversial, because the physical presence of parasites in
the brain microvessels has not been unequivocally dem-
onstrated in all patients who die of CM. Moreover,
patients with CM can recover from deep, prolonged
coma associated with protracted seizures, hypoglyce-
mia, and severe anemia, without any sequelae [6, 7].
Nonetheless, African children with severe neurological
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NEC 9 … 34 (2.2–42.4) 8/1
EC 14 … 27 (24.9–29.2) 13/1
MM 33 1.2 (0.7–2.1) 28.4 (23.8–34) 13/20
SM 14 1.1 (0.3–3.2) 25.7 (15.85–41.8) 8/6
CM 26 2 (1–3.87) 33.3 (26–42.8) 12/14
Ex-CM 8 … 19.3 (7.35–50.9) 3/5
Total 104 … 28.9 (25.9–32.2) …
NOTE. CM, cerebral malaria; EC, endemic control (healthy control subjects from
malaria-endemic areas); ex-CM, recovered from CM; MM, mild malaria; NEC, nonen-
demic control (healthy control subjects from non–malaria-endemic areas); SM, non-
cerebral severe malaria.
sequelae (e.g., spastic tetraparesis and vegetative states) usually
die within a few months of discharge from the hospital [8, 9].
Proinflammatory (Th1) cytokines such as tumor necrosis
factor (TNF)–a are also thought to play an important role in
malaria pathogenesis, particularly in CM, by increasing the sur-
face expression of adhesion molecules on cerebral endothelial
cells that enhance parasite attachment [6, 10–12]. Excessive
production of TNF-a in patients with CM seems to be a con-
sequence of genetic variation in the host’s propensity to pro-
duce this cytokine [13–16]. Furthermore, increased plasma lev-
els of TNF-a, together with increased production of interferon
(IFN)-g, interleukin (IL)–1b, and IL-6 and reduced production
of IL-4 and transforming growth factor (TGF)-b, have been
reported in patients with SM [17, 18]. Conversely, IFN-g and
TNF-a are involved in effector mechanisms conferring pro-
tection against Plasmodium infection [19–21].
The role of anti-inflammatory cytokines in malaria severity
remains controversial, because different studies have reported
high concentrations of IL-10 as being associated either with
SM or with protection against SM in humans [17, 22–24]. In
addition, it has been shown that the balance between IL-10
and TNF-a concentrations determines the severity of anemia
in infected children [25]. Along the same line of evidence,
plasma levels of TGF-b, a cytokine that acts at high concen-
trations as an anti-inflammatory cytokine, are inversely cor-
related with malaria severity in murine models as well as in
humans. In a recent study performed in Kenya, lower levels of
TGF-b in serum and cerebrospinal fluid from children with
CM were found to be associated with higher levels of TNF-a
[26]. Indeed, the outcome of P. falciparum infection may de-
pend on a fine balance between appropriate and inappropriate
induction of these immune regulatory factors.
Although cytokines have been implicated in the pathogenesis
of malaria, their specific involvement in terms of different
groups/clusters correlating with MM, SM, and CM has not yet
been defined. To better determine the role played by pro- and
anti-inflammatory cytokine levels and their ratios in malaria
severity, we analyzed the association between plasma levels of
IFN-g, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, TNF-a, and
TGF-b in clinically well-defined groups of P. falciparum–in-
fected patients from Gondia, a district of Maharashtra State in
central India, with MM, SM, or CM and compared these pa-
tients with control subjects from malaria-endemic and non–
malaria-endemic areas and with subjects who have recovered
from CM. We also studied the association between plasma cy-
tokine network profiles and parameters such as age and sex of
the patients, parasitemia level, and disease severity. We found
that cytokines such as IL-1b, IL-12, and IFN-g discriminated
CM from SM, that high IL-1b levels were associated with CM,
and that high IL-12 and IFN-g levels were associated with non-
cerebral SM. Moreover, disease severity in patients with malaria
was independent of parasitemia level, sex, and age.
SUBJECTS, MATERIALS, AND METHODS
Study population. The present study was performed in the
Gondia District of Maharashtra State, India. Categorization of
malaria cases was performed by the resident physician of the
hospital on the basis of severity criteria defined by the World
Health Organization. Patients with MM ( ) were out-np 33
patients and not admitted to the hospitals. Patients with SM
( ) were fully conscious and were able to respond wellnp 14
verbally to the doctors’ questions. Patients with CM ( )np 26
were in a comatose state. In addition, 3 groups of control
subjects were defined: (1) subjects who had CM within the past
6 months and recovered (“ex-CM subjects”; ), (2) healthynp 8
subjects from malaria-endemic areas (“endemic control sub-
jects”; ), and (3) healthy subjects from non–malaria-np 15
endemic areas (“nonendemic control subjects”; ), of bothnp 9
sexes. The age of the patients with malaria ranged from 5 to
75 years. Blood samples from endemic control subjects were
collected from patient’s relatives (brothers/sisters/parents) who
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Figure 1. Differences in plasma cytokine levels in clinical malaria groups. Levels (pg/mL) of interferon (IFN)–g, interleukin (IL)–1b, IL-2, IL-4, IL-5,
IL-6, IL-10, IL-12, tumor necrosis factor (TNF)–a, and transforming growth factor (TGF)–b were determined by ELISA from 1-time blood samples collected
from patients before administration of drugs. CM, cerebral malaria; EC, endemic control (healthy control subjects from malaria-endemic areas); ex-
CM, recovered from CM; MM, mild malaria; NEC, nonendemic control (healthy control subjects from non–malaria-endemic areas); SM, severe noncerebral
malaria. Horizontal bars indicate the respective groupwise medians.
accompanied the patient to the hospital. These persons had
not had malaria for at least 2 years, nor were they clinical
asymptomatic carriers; their blood smears were checked for the
presence of malarial parasites. Blood samples from nonendemic
control subjects (from the city of Pune) were collected from
our laboratory colleagues with no history of malarial disease
for 5 years. All consent from donors, patients, and relatives
was obtained before blood collection.
Blood-sample collection. Blood samples were collected dur-
ing 2001–2003 from different hospitals in Gondia: ∼10–20 mL
of peripheral venous blood was collected either in EDTA or in
sterile vacutainers. Plasma was obtained by centrifuging the
blood samples at 4500 g for 15 min and was stored at 80C
until further use.
Parasite assessment. A thin blood smear was prepared, air-
dried, fixed in methanol, and stained with JSB1 (methylene
blue) and JSB2 (eosin). The total numbers of infected and un-
infected erythrocytes from ∼10 fields (magnification, 100)
were counted, and parasitemia levels were calculated.
Cytokine assays. The levels of cytokines (IL-1b, IL-2, IL-
4, IL-6, IL-10, IL-12, TGF-b, TNF-a, and INF-g) in plasma
were estimated by use of Opti-EIA kits (BD-Pharmingen), used
per the manufacturer’s instructions. Briefly, flat-bottom 96-
microwell plates (Nunc Maxisorb P/N) were coated overnight
at 4C with capture antibody diluted in 0.1 mol/L carbonate
buffer, pH 9.5. After washing with PBS–0.05% Tween-20 and
blocking with PBS–10% FBS for 1 h at room temperature, 100
mL of plasma from either patients or control subjects was added
to each coated well and incubated for 2 h at 20C. All assays
were performed in triplicate. A standard curve was determined
for each cytokine, using serial dilutions of the different human
recombinant cytokines. Cytokine concentrations were calcu-
lated after incubation with peroxidase-conjugated anti–human
cytokine antibodies. The peroxidase activity was revealed with
tetramethyl benzidine. Unknown sample cytokine concentra-
tions were calculated from the standard curves. Means and SDs
were calculated from the values.
Statistical analysis. Comparisons between groups were cal-
culated by Mann-Whitney rank sum test. Coupled 2-way cluster
analysis was performed using an algorithm (available at: http:
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Figure 2. Two-way coupled cluster analysis. Each cell in the 2-dimensional graph indicates the measure of a single cytokine in 1 sample, with
standardized levels indicated by color according to the scale on the right. Hierarchical clusters for both samples and cytokines were obtained as
described (see Subjects, Materials, and Methods). Sample clustering resulting from the algorithm applied is shown at the top of the graph as a
horizontal dendrogram, with an indication of the group to which each individual sample belongs. Major clusters—which discriminated the clinical
groups exactly, with the exception of 1 sample—are separated throughout the graph by vertical lines. Cytokine clustering is depicted analogously in
a vertical order to the left of the graph. CM, cerebral malaria; EC, endemic control (healthy control subjects from malaria-endemic areas); ex-CM,
recovered from CM; IFN, interferon; IL, interleukin; MM, mild malaria; SM, severe malaria; TGF, transforming growth factor; TNF, tumor necrosis factor.
//ctwc.weizmann.ac.il), as described by Getz et al. [27] and Blatt
et al. [28]. Missing data were replaced by overall means. Clus-
tering was performed on log-transformed data with no dropout
constraints until single entities were reached. Clusters were con-
sidered to be stable when they remained over 8 cycles, according
to the default settings by the authors of the algorithm. Default
settings were also used for the other framework conditions: T
increasing from 0 to 0.25, with 0.004 increments/cycle.
Linear discriminant analysis was also performed on log-trans-
formed data, rejecting samples with incomplete information. The
significance of contributing parameters was calculated by back-
ward elimination—that is, by partial F tests on variances ex-
plained by models with or without a respective parameter. The
significance criterion was a Bonferoni-corrected P value !.05. For
this purpose, special macros in addition to the software IgorPro
(version 3.16; WaveMetrics) were used.
RESULTS
Age, sex distribution, and parasitemia in the different clinical
groups. We compared the age and sex distribution of P. fal-
ciparum–infected patients manifesting different degrees of se-
verity of clinical malarial disease—that is, CM, SM, and MM.
The clinical severity was uniformly spread over both sexes and
all age groups. Susceptibility to CM was not restricted to chil-
dren and was also seen in older people (table 1). Parasitemia
levels ranged from 0.1% to 7.50% in the different groups; 3
patients with CM had exceptionally high parasitemia levels
(20.25%, 25.5%, and 60%). However, neither malaria disease
severity nor age nor sex showed any correlation with blood
parasitemia level (table 1). Thus, disease severity in Gondia
P. falciparum–infected patients seemed to be independent of
parasitemia.
Cytokine levels. Profiles of IFN-g, IL-1b, IL-2, IL-4, IL-5,
IL-6, IL-10, IL-12, TNF-a, and TGF-b were determined by
ELISA on a 1-time blood sample collected from the different
groups of patients before administration of drugs. Median
plasma levels of the different cytokines are shown in figure 1.
The levels of IL-1b, IL-10, TNF-a, and TGF-b were observed
to be most significantly increased in the CM group, compared
with those in the endemic control group or in the other groups
of P. falciparum–infected patients (for all comparisons, P !
). Interestingly, these cytokines were also present, in mod-610
erate concentrations, in plasma from the ex-CM group. The
levels of IL-1b, IL-10, and TNF-a were only marginally in-
creased in the endemic control group, compared with those in
the nonendemic control group; however, levels of IL-2, IL-12,
and IFN-g were lower in the CM group than in the SM group.
There was no difference in levels of IL-2 and IFN-g between
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Figure 3. Relationships of cytokines represented in cluster 1. Log-transformed distributions of plasma levels (in pg/mL) of the cytokines represented
in cluster 1 (interferon [IFN]–g, interleukin [IL]–2, IL-5, IL-6, and IL-12) are depicted pairwise. Patient groups are denoted as follows: minus signs (),
nonendemic control (NEC; healthy control subjects from non–malaria-endemic areas); plus signs (+), endemic control (EC; healthy control subjects from
malaria-endemic areas); white circles, mild malaria (MM); crossed circles, noncerebral severe malaria (SM); black circles, cerebral malaria (CM);
diamonds, recovered from CM (ex-CM). Mean and SD for each group are denoted by error bars.
the MM group and the SM group, although IL-12 levels were
significantly higher in the MM group.
Evidently, cytokine levels thus had the power to discriminate
between clinical forms of malaria in the samples we studied.
Therefore, to characterize the overall cytokine patterns relevant
to each clinical subgroup of disease manifestation, we applied
a coupled 2-way cluster analysis [27, 28]. This method allows
coupled clustering of both the patients and the measured pa-
rameters without taking into account the clinical diagnosis.
Since IL-5 levels were not determined for the nonendemic con-
trol subjects, only endemic control subjects and ex-CM subjects
were included in addition to patients with clinical malaria. As
is shown in figure 2, uninfected subjects (control and ex-CM)
and patients with MM, SM, or CM segregated perfectly, with
the exception of 1 patient with SM located in the cluster of
patients with MM. However, this single misclassification rep-
resents 1 of 2 serum samples that had been taken from patients
1 day after commencement of antimalarial therapy.
The clustering of cytokines coupled with the classification of
individuals identified 2 major clusters, which categorized all
cytokines measured except IL-4 (figure 2). The first cluster
included IFN-g, IL-2, IL-5, IL-6, and IL-12, the levels of which
are significantly increased during infection—predominantly in
patients with MM—and decrease with malaria severity, with
the exception of IL-12, the levels of which remain enhanced
compared with those in the endemic control subjects and ex-
CM subjects. This presents a convenient mechanism for dis-
crimination of the MM group from the SM and CM groups.
An interesting observation is that IL-6 levels were lower in the
SM group than in the CM group. Levels of IFN-g appeared to
be most correlated with those of IL-2, being higher in infected
patients than in control subjects but significantly lower in pa-
tients with CM than in patients with MM or SM (between
which the difference was not significant) (figure 3G). In con-
trast, high IL-5 and IL-6 levels in plasma distinguished the MM
group from the 2 severe-malaria groups, which exhibited low
and intermediate levels of IL-6 and IL-5, respectively, whereas
levels of both cytokines were low in endemic control and ex-
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Figure 4. Relationships of cytokines represented in cluster 2. Log-transformed distributions of plasma levels (in pg/mL) of the cytokines represented
in cluster 2 (transforming growth factor [TGF]–b, tumor necrosis factor [TNF]–a, interleukin [IL]-10, and IL-1b) are depicted pairwise. Mean and SD
for each group are denoted by error bars. For symbols and abbreviations, see figure 3.
CM subjects (figure 3I). Most remarkably, IL-12 completely
discriminated all 3 clinical forms, in that its levels were inverse-
ly proportional to disease severity—that is, they continuously
decreased with increasingly severe malaria manifestation. This
trend paralleled one seen with another cytokine in this group—
namely, IL-2—but IL-12 was clearly more characteristic of the
clinical form and was less influenced by the level of infection
per se (figure 3B).
The second cluster consisted of TGF-b, TNF-a, IL-10, and
IL-1b. Levels of all of these cytokines were highly correlated
with each other when all the different clinical groups of patients
were considered, and they significantly increased with disease
severity. It is worthy of note that, in the ex-CM group, the
levels of these cytokines (except IL-10) decreased to levels com-
parable to those in the endemic control groups. Levels of TGF-
b in the MM group did not differ from those in the endemic
control groups, whereas they were lower in the nonendemic
control group (figure 4). The general results can be best rep-
resented by the distribution of IL-12 versus IL-10 in the dif-
ferent groups studied: a continuous increase in levels of cluster-
2 cytokines with disease severity is associated with reductions
in levels of cluster-1 cytokines that are individually fine-tuned
(figure 5).
Discriminant analysis of cytokine profiles in patients with
malaria. Cytokines were represented in the same cluster, be-
cause of correlations among them (figure 2). Such correlation
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Figure 5. Relationship between distributions of interleukin (IL)–12 and
IL-10. Shown is the 2-dimensional distribution of IL-12 and IL-10, as the
most characteristic representatives for cluster-1 and cluster-2 cytokines,
respectively, in pg/mL. Mean and SD for each group are denoted by error
bars. For group symbols, see figure 3. A continuous increase in levels of
cluster-2 cytokines (transforming growth factor [TGF]–b, tumor necrosis
factor [TNF]–a, IL-10, and IL-1b ) with disease severity is associated with
a reduction in levels of cluster-1 cytokines (interferon [IFN]–g, IL-2, IL-5,
IL-6, and IL-12).
implies that differences found for a single cytokine in relation
to clinical forms may indicate either (1) a functional association
between the cytokine and a specific pathology or (2) that it
follows the same general trend as any another functionally as-
sociated factor. Discriminant analysis is a method that is, in
principle, capable of estimating these 2 possibilities within a
given panel of parameters. Thus, to identify the most likely
genuinely associated cytokines among the panel reported above,
rather than those that are secondarily associated with a partic-
ular manifestation of malaria, we performed a series of discrim-
inant analyses. First, we performed a linear discriminant anal-
ysis, including the same groups as the above cluster analysis,
with the exception of the ex-CM group.
The resulting 2-factor representation is depicted in figure 6A,
which shows complete separation of 4 groups and shows that
2 resulting factors account for infection (factor 1, horizontal)
and clinical forms (factor 2, vertical). To resolve the different
possible effects separately, we performed more-specific analyses,
as indicated in the figure by dashed lines, for infection (dis-
crimination A), severity (discrimination B), and CM (discrim-
ination C). Cytokines relevant to each type of discrimination
are annotated. When discriminating infection, we found that
levels of IL-5, IL-1b, IL-10, and IL-2 increased with infection,
thereby contributing significantly (in the order indicated, with
IL-5 having the highest impact). When discriminating SM from
MM, we noted that IL-12, IL-5, and IL-6 were relevant, in that
levels of all 3 were relatively increased in the MM group. Finally,
IL-1b, IL-12, and IFN-g seemed relevant for the discrimination
of CM from SM. High IL-1b levels were associated with CM,
and high levels of IL-12 and IFN-g were associated with SM.
These results are summarized in a minimal model (figure 6B).
DISCUSSION
The balance between pro- and anti-inflammatory cytokines
plays a pivotal role in the regulation of immune responses and
pathogenesis in P. falciparum malaria, although, to date, their
role in disease pathogenesis and relationship to host protection
have remained unclear. In the present study, we directly ad-
dressed the relationship between the clinical severity of malaria
and the complex pro- and anti-inflammatory cytokine network
in subjects from the Gondia District of Maharashtra State, In-
dia. As reported above, malaria disease severity in patients was
found to be independent of parasitemia, sex, and age.
Multivariate cluster and discriminant analyses suggest a 2-
component model of clinical forms of malaria-related cytokine
responses. As a first component, a response with protective
properties against severe clinical forms is clearly indicated in
our analysis by cytokine cluster 1, which is best represented by
IL-12. IL-12 has been shown to be down-regulated in SM but
not in mild P. falciparum malaria [29]. A study performed in
Gabonese children revealed low IL-12 levels in SM, suggesting
that the inflammatory cascade in SM is characterized by sup-
pression of protective effects of IL-12 [30]. Additionally, an
increase in IL-12 levels during the acute phase of uncomplicated
P. falciparum malaria is thought to reflect an early and effective
immune response regulated by proinflammatory Th1 cytokines
[31]. Cluster 1 also includes IFN-g and IL-2 and appears to be
a Th1-type cytokine network. IFN-g is a critical mediator of
immunity to malaria and is generally associated with protective
mechanisms [32, 33]. This association between proinflamma-
tory cytokines and MM is in agreement with previous studies
indicating that an increase in IL-2 levels during the acute phase
of uncomplicated P. falciparum malaria could affect an early
and effective response regulating Th1 cytokines [31]. Increased
levels of IFN-g were detected in serum from patients with
uncomplicated malaria but were also detected in those with
SM and CM in a study in Bangkok [34]. In our study, this
network also involved the induction of IL-5 and IL-6, levels
of which were found to be inversely correlated with disease
severity as well. This is in contrast to previous studies showing
levels of IL-6 to be increased in SM [35]. It would be interesting
to explore further the association between malaria severity and
IL-5, which has so far been studied to a very limited extent in
this context.
Pathogenic Th1-type responses have been suggested to be
down-regulated by factors such as IL-10 [36], but protective
Th1-type immunity can be also down-regulated and suppressed
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Figure 6. Linear discriminant analysis (LDA) of the cytokine profiles in Plasmodium falciparum–infected patients and healthy control subjects from
malaria-endemic areas (endemic control [EC]). A, Factors 1 and 2 resulting from LDA, discriminating the EC, mild malaria (MM), severe noncerebral
malaria (SM), and cerebral malaria (CM) groups according to their cytokine profiles. The completely separated 4 groups were further studied by more-
specific discriminant analyses, indicated in the figure by dashed lines, for infection (between EC and all other groups; discrimination A), severity
(between MM and severe forms; discrimination B), and CM (against SM; discrimination C). Annotations indicate the cytokines that turned out to be
relevant for each type of discrimination, in their respective order of significance calculated by backward elimination. B, Minimal model summarizing
the cytokine effects that were found to be significant for each type of discrimination.
in severe forms of malaria by a second type of response triggered
by plasmodial infection [37, 38]. Our results are in agreement
with the interpretation that such a “regulatory” response, as it
was recently referred to [38], is represented by cytokine cluster
2. We found the highest levels of TNF-a, IL-1b, TGF-b, and
IL-10 in the CM group, followed by SM group and then by
the MM group. These results are in line with earlier findings
showing increased levels of TNF-a, IL-10, and IL-1b in plasma
from patients with SM [37–40]. Immunohistochemical staining
of brain sections from patients with CM indicates tissue-lo-
calized production of TNF-a, IL-1b, and IL-10 (besides IFN-
g) in association with malaria pathology [41]. The most char-
acteristic cytokine of this cluster is IL-10, which is known to
be a pleiotropic immunomodulatory cytokine regulating not only
Th1- but also Th2-type reactions in many instances [42–45].
However, the role of IL-10 in malaria is still controversial, because
high levels have been shown to be associated with both severe
disease and protection against P. falciparum infections [17, 30,
37, 40, 46]. IL-10 also shows the best evidence of a direct rela-
tionship with parasitemia, as has been demonstrated in children
with high-density parasitemia [25] that reflects functionally less
effective parasite clearance [47]. Our results fall in line with those
of earlier studies, in which plasma levels of IL-10 were high in
patients with CM [17]. However, a study performed in Bangkok
indicated that serum levels of IL-10 and IFN-g were markedly
increased in patients with acute malaria [41]. The high levels of
IL-10 associated with significantly low percentages of lympho-
cytes producing IL-4 during malaria suggest an immunoreg-
ulatory role rather than a Th2 activity [48]. In line with this
hypothesis, IL-10 has been shown to inhibit the production of
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TNF-a, IL-1b, IL-6, and IFN-g [49], the latter 2 of which are
cytokines found in cluster 1, associated with MM in our groups
of patients. Interestingly, the “regulatory” response in our sam-
ples did not appear to follow a strict Th1/Th2 cytokine network
scheme but was instead characterized by parallel increases in
levels of IL-1b, TNF-a, and TGF-b. A burst of TGF-b, the
presence of CD4+CD25+FOXP3+ regulatory T cells, and a de-
crease in proinflammatory cytokine production have recently
been found to be associated with higher rates of parasite growth
in P. falciparum–infected volunteers [50].
Discriminant analysis showed that TNF-a and TGF-b did
not significantly contribute to any group discrimination, a find-
ing that is compatible with the possibility that these cytokines
follow a pattern that is, rather, determined by other factors (as
is the case with IL-10) without necessarily influencing the path-
ogenic process directly. The critical role of TNF-a in human
CM has indeed been brought into question by the failure of
TNF-a–neutralizing reagents to decrease the incidence of clin-
ical CM [51, 52]. In contrast, increased IL-1b levels contributed
significantly to the discrimination of CM in our population,
supporting a direct pathogenic relevance. Significantly higher
IL-1b levels have been observed in serum samples from patients
with SM [53]. IL-1b mRNA has been detected in postmortem
brain tissue samples from patients with CM, whereas it was
absent from normal brain tissue [54].
Finally, our results suggest that the inflammatory cascade in
SM is characterized by suppression of the protective effects of
type 1 cytokines, such as IL-12, and that overproduction of
TNF-a and IL-1b may promote deleterious effects. These mol-
ecules have an effective role in the pathogenesis of malaria, and
their levels can be useful as diagnostic markers for malaria and
for monitoring the severity of the disease [55]. Although each
cytokine has its unique function, most cytokines exhibit a wide
range of biological effects that act simultaneously on a partic-
ular cell type. This creates a complex cytokine network, which
makes a precise correlation with malaria severity difficult. In
conclusion, mechanisms linking cytokines with biochemical as-
pects of cell activation, regulation, and adhesion-molecule ex-
pression in the microvasculature seem to emerge as potential
modulators of malaria severity. On the basis of these obser-
vations, measurement of panels of cytokines could be helpful
for diagnosis.
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